A new report by EY has revealed that despite tariff uncertainty, the medtech industry has recorded its seventh successive year of top-line growth to reach a valuation of $584bn in the 12 months ended 30 June, with the sector on course to record 6% to 7% revenue growth by the end of 2025. EY’s Pulse of the MedTech Industry report found that medtech VC investments were up 16% in the first half of the year compared with the same period in 2024, with average financing rounds reaching $36m, reflecting a 122% i ...